Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine.

Nolan T, Richmond P, Marshall H, McVernon J, Alexander K, Mesaros N, Aris E, Miller J, Poolman J, Boutriau D.

Pediatr Infect Dis J. 2011 Mar;30(3):190-6. doi: 10.1097/INF.0b013e3181fcb2bf.

PMID:
20948453
2.

Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.

Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, Boutriau D; HibMenCY-TT 005 Study Group..

Pediatr Infect Dis J. 2010 Jan;29(1):48-52. doi: 10.1097/INF.0b013e3181c3ce88.

PMID:
20035207
3.

Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age.

Marshall GS, Marchant CD, Blatter M, Aris E, Boutriau D, Poolman JT, Friedland LR, Miller JM.

Pediatr Infect Dis J. 2010 May;29(5):469-71. doi: 10.1097/INF.0b013e3181cdd379.

PMID:
20072077
4.
5.

Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger.

Campagne G, Garba A, Fabre P, Schuchat A, Ryall R, Boulanger D, Bybel M, Carlone G, Briantais P, Ivanoff B, Xerri B, Chippaux JP.

Pediatr Infect Dis J. 2000 Feb;19(2):144-50.

PMID:
10694002
6.

Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.

Tejedor JC, Merino JM, Moro M, Navarro ML, Espín J, Omeñaca F, García-Sicilia J, Moreno-Pérez D, Ruiz-Contreras J, Centeno F, Barrio F, Cabanillas L, Muro M, Esporrin C, De Torres MJ, Caubet M, Boutriau D, Miller JM, Mesaros N.

Pediatr Infect Dis J. 2012 Oct;31(10):1074-7.

PMID:
22828645
7.

Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.

Hu JL, Tao H, Li JX, Dai WM, Song B, Sun JF, Liu P, Tang J, Liu WY, Wang SY, Zhu FC.

Hum Vaccin Immunother. 2015;11(5):1120-8. doi: 10.1080/21645515.2015.1033592.

8.

Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers.

Bryant KA, Marshall GS.

Expert Rev Vaccines. 2011 Jul;10(7):941-50. doi: 10.1586/erv.11.90. Review.

PMID:
21806393
9.

A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.

Pace D, Snape M, Westcar S, Hamaluba M, Yu LM, Begg N, Wysocki J, Czajka H, Maechler G, Boutriau D, Pollard AJ.

Pediatr Infect Dis J. 2007 Nov;26(11):1057-9.

PMID:
17984816
10.

Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.

Tejedor JC, Moro M, Merino JM, Gómez-Campderá JA, García-del-Rio M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Ruiz-Contreras J, Martin-Ancel A, Roca J, Boceta R, García-Corbeira P, Maechler G, Boutriau D; Spanish 102547 Study Group..

Pediatr Infect Dis J. 2008 Jul;27(7):579-88. doi: 10.1097/INF.0b013e31816b4561.

PMID:
18536619
11.

Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age.

Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM.

Pediatr Infect Dis J. 2011 Mar;30(3):e41-8. doi: 10.1097/INF.0b013e3182054ab9.

PMID:
21200360
12.

Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age.

Marshall GS, Blatter M, Marchant C, Aris E, Mesaros N, Miller JM.

Pediatr Infect Dis J. 2013 Jun;32(6):662-8. doi: 10.1097/INF.0b013e3182840e35.

PMID:
23340564
13.

The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants.

Mulholland EK, Byass P, Campbell H, Fritzell B, Greenwood AM, Todd J, Greenwood BM.

Ann Trop Paediatr. 1994;14(3):183-8.

PMID:
7825990
14.

Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age.

Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G, Ziegler JB, Heron L, Lambert S, Caubet M, Mesaros N, Boutriau D.

Pediatr Infect Dis J. 2011 Apr;30(4):340-2. doi: 10.1097/INF.0b013e31820013d2.

PMID:
21068692
15.

The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.

Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, Poolman J, Schuerman L, Dobbelaere K, Boutriau D.

Int J Infect Dis. 2008 May;12(3):278-88. Epub 2007 Nov 5.

16.

Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.

Chotpitayasunondh T, Panpitpat C, Thisyakorn U, Furer E, Que JU, Hasler T, Cryz SJ Jr.

Southeast Asian J Trop Med Public Health. 1997 Mar;28(1):91-8.

PMID:
9322290
17.

Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.

Punjabi NH, Richie EL, Simanjuntak CH, Harjanto SJ, Wangsasaputra F, Arjoso S, Rofiq A, Prijanto M, Julitasari, Yela U, Herzog C, Cryz SJ.

Vaccine. 2006 Mar 10;24(11):1776-85. Epub 2005 Oct 27.

PMID:
16303216
18.

A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.

McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C.

Pediatr Infect Dis J. 2012 Jan;31(1):e15-23. doi: 10.1097/INF.0b013e31823e1e34.

PMID:
22094636
19.

Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine.

Greenberg DP, Wong VK, Partridge S, Chang SJ, Jing J, Howe BJ, Ward JI.

Pediatr Infect Dis J. 2000 Dec;19(12):1135-40.

PMID:
11144372
20.

Reactogenicity and immunogenicity of combined Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccine.

Carmona A, Miranda M, Barrio F, De Vicente A, Mares J, Muñoz E, Diez-Delgado J, Alonso A, Giménez-Sánchez F, Merino J, García-Corbeira P, Maechler G, Boutriau D; Spanish 103954 Study Group..

Pediatr Infect Dis J. 2010 Mar;29(3):269-71. doi: 10.1097/INF.0b013e3181c15977.

PMID:
19952860

Supplemental Content

Support Center